← Back to List
Dossier•0 Views

TILA-278 — Regulatory Dossier: Reader's Guide

July 13, 2026

TILA-278 — Regulatory Dossier: Reader's Guide

🧪
Mock / simulation document

This is a mock / simulation document, made for a portfolio and for learning. The drug (GLPI-103), the sponsor, the people, and the data are all fictional. It is not a real regulatory submission and has no clinical, legal, or regulatory standing. What is real is the shape of the thing — the document structure, the standards it follows, and the analysis methods; the content inside is illustrative.

📚
What this is

A walk-through of the clinical CTD summaries for a virtual drug — TILA-278, an anti-TL1A / IL-22 bispecific antibody for moderate-to-severe ulcerative colitis. Each linked article opens with a plain-language guide and then shows the live document. Every clinical figure comes from one simulated Phase 2b induction study, with the mechanistic efficacy modelled by the CSB engine; it is a portfolio demonstration, not a real submission.

🗺️
How a submission is organized (the CTD)

Marketing applications worldwide share the ICH Common Technical Document (CTD), a five-module structure. Module 1 is region-specific admin and labeling; Module 2 is the high-level summaries a reviewer reads first; Module 3 is quality / manufacturing (CMC); Module 4 is the animal (nonclinical) studies; Module 5 is the human clinical studies and data. The Trial Master File, program-management, and quality documents are the operational records that stand behind the trial.

Every document, explained

Module 1 — Regional & Administrative

Module 2 — CTD Summaries & Overviews

Module 3 — Quality (CMC)

Module 4 — Nonclinical (Animal) Study Reports

Module 5 — Clinical Study Reports & Data

Trial Master File — how the trial is run

Program Management

Quality

Portfolio project. The drug, sponsor, and data are fictional; the standards, methods, and document structure are real.

Comments (0)

No comments yet. Be the first to say something!